AOP Orphan Pharmaceuticals AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

Phase 3

Active, not recruiting

Conditions: Essential Thrombocythaemia

Interventions: Drug: Ropeginterferon alfa-2b (BESREMi®)

First Posted Date: 2024-07-23

Last Posted Date: 2024-12-19

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 117

Registration Number: NCT06514807

Locations: 🇦🇹
University Hospital Graz, Department of Internal Medicine, Clinical Department of Hematology, Graz, Styria, Austria
🇦🇹
Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Tyrol, Austria
🇦🇹
Ordensklinikum Linz GmbH Elisabethinen Hospital, Department of Internal Medicine I - Hemato-Oncology, Linz, Upper Austria, Austria

and more 33 locations

A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

Conditions: Pulmonary Arterial Hypertension

First Posted Date: 2024-06-06

Last Posted Date: 2024-08-07

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 110

Registration Number: NCT06445673

Locations: 🇫🇷
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
🇦🇹
Ordensklinikum Linz, Linz, Austria
🇦🇹
Medical University Vienna, Vienna, Austria

and more 15 locations

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Phase 3

Recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: preservative-free parenteral treprostinil

First Posted Date: 2024-04-05

Last Posted Date: 2024-08-07

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 20

Registration Number: NCT06350032

Locations: 🇪🇸
Ramón y Cajal University Hospital, Madrid, Spain
🇫🇷
Necker-Enfants Malades Hospital, Paris, Paris, France
🇭🇺
Gottsegen National Cardiovascular Center, Budapest, Hungary

and more 1 locations

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

Phase 4

Recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Generic treprostinil sodium + Standard of Care (Double Oral)
Drug: Standard of Care - Double Oral

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-19

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 110

Registration Number: NCT06317805

Locations: 🇵🇱
Fryderyk Chopin Hospital in European Health Centre Otwock, Otwock, Poland
🇦🇹
Medical University Vienna, Vienna, Austria
🇷🇴
Emergency Clinical County Hospital of Targu Mures, Târgu-Mureş, Romania

and more 16 locations

Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients

Phase 3

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen

First Posted Date: 2015-08-14

Last Posted Date: 2016-02-17

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 30

Registration Number: NCT02523638

Locations: 🇺🇦
Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine
🇭🇺
University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged, Hungary
🇺🇦
O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, Ukraine

and more 32 locations

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Phase 3

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Best available therapy (BAT)
Drug: Pegylated-Proline-interferon alpha-2b

First Posted Date: 2014-08-15

Last Posted Date: 2021-06-01

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 170

Registration Number: NCT02218047

Locations: 🇸🇰
University Hospital with Outpatient Clinic F.D. Roosevelt, Banska Bystrica, Slovakia
🇵🇱
Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland
🇷🇴
Bucharest University Emergency Hospital, Bucharest, Romania

and more 44 locations

Anagrelide Retard in Essential Thrombocythemia

Phase 3

Completed

Conditions: Essential Thrombocythemia

Interventions: Drug: Anagrelide retard
Drug: Thromboreductin

First Posted Date: 2014-03-04

Last Posted Date: 2015-07-29

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 106

Registration Number: NCT02076815

Locations: 🇱🇹
AOP Orphan Investigational Site Lithuania 2, Klaipeda, Lithuania
🇵🇱
AOP Orphan Investigational Site Poland 5, Bialystok, Poland
🇧🇬
AOP Orphan Investigational Site Bulgaria 2, Sofia, Bulgaria

and more 16 locations

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera

Phase 3

Completed

Conditions: Polycythemia Vera

Interventions: Drug: Peg-P-IFN-alpha-2b (AOP2014)
Drug: Hydroxyurea

First Posted Date: 2013-09-25

Last Posted Date: 2016-11-28

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 257

Registration Number: NCT01949805

Locations: 🇧🇬
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria
🇩🇪
University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III, Bonn, Germany
🇵🇱
Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland

and more 55 locations

Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LDLL600
Drug: Brevibloc

First Posted Date: 2012-12-05

Last Posted Date: 2015-04-21

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 14

Registration Number: NCT01741519

Locations: 🇨🇿
Cepha s.r.o, Pilsen, Czech Republic

A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Esmolol hydrochloride
Drug: ONO LDL50
Drug: LDLA202

First Posted Date: 2012-07-30

Last Posted Date: 2012-09-05

Lead Sponsor: AOP Orphan Pharmaceuticals AG

Target Recruit Count: 12

Registration Number: NCT01652898

Locations: 🇨🇿
Cepha s.r.o, Pilsen, Czech Republic

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy